Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, which conditions are considered a priority by the Medicines and Healthcare products Regulatory Agency when assessing applications for new licences for medicines.

The Medicines and Healthcare products Regulatory Agency (MHRA) does not have a specific list of conditions to which it gives priority when reviewing applications for new medicine licenses. However, it does prioritise applications where there is a public health need, for instance a new medicine which offers a treatment which is not yet available or a generic medicine where there might otherwise be a risk to supply. When deciding whether to prioritise a medicine, the MHRA collaborates with the Department and National Health Service to make sure its decisions align with their priorities.